Genfit S.A. (GNFT.PA) News
Track canonical SquawkNews coverage tagged to GNFT.PA, Genfit S.A.. This hub brings together deduplicated headlines about paris, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
DWS Investment cuts Genfit stake to 3.77%
DWS Investment crossed below the 5% capital threshold in Genfit on Sept. 15, 2026. Holding fell to 1,890,115 shares, equal to 3.77% of capital, from 2,626,474 shares, or 5.24%, on Sept. 11. Voting rights position dropped
EQUITY | Sep 18, 2026, 02:17 PM UTC
L
Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement
() -- Genfit (GNFT.PA) said Thursday its non-invasive blood test Nashnext was approved for coverage and future reimbursement by US Medicare. The Paris-listed biopharmaceutical company, which licensed the test to Labcorp,
EQUITY | Jul 03, 2026, 04:58 AM UTC